Incretin Therapies for Patients with Type 2 Diabetes and Chronic ...

SGLT2 inhibitor and incretin mimetic therapy for type 2 diabetes and ...

It is an exciting time in the field of diabetes and chronic kidney disease. Newer glucose-lowering drugs—both SGLT2 inhibitors and GLP-1 ...

Breaking New Ground with Incretin Therapy in Diabetes | NEJM

Cited by. Radica Z. Alicic,; Joshua J. Neumiller,. Incretin Therapies for Patients with Type 2 Diabetes and Chronic Kidney Disease, Journal of Clinical Medicine ...

Incretin Therapies in the Management of Elderly Patients with Type ...

“Incretin therapies,” comprising the injectable GLP-1 analogs and oral dipeptidyl peptidase-4 (DPP-4) inhibitors, are promising new therapies ...

Incretin mimetics and dipeptidyl peptidase-4 inhibitors: innovative ...

The prevalence of diabetes and impaired glucose tolerance is predicted to dramatically increase over the next two decades. Clinical therapies for type 2 ...

Incretin-based therapies for patients with type 1 diabetes: a meta ...

Objective Combined treatment with an incretin-based drug, such as a glucagon-like peptide 1 receptor agonist (GLP-1 RA) or a dipeptidyl peptidase-4 (DPP-4) ...

Gallbladder Diseases and Incretin Drugs in Type 2 Diabetes Mellitus

According to the World Health Organization event database, the use of incretin-based drugs has been reported in 1069 cases of bile duct or ...

Novel Incretin-Based Agents and Practical Regimens to Meet Needs ...

Novel strategies for the treatment of patients with type 2 diabetes mellitus (T2DM) engage the incretin system. ... treatment of patients with ...

Incretin treatment and risk of pancreatitis in patients with type 2 ...

12 The number of cancer cases did not seem larger in patients taking incretins (except exenatide) than other drugs for diabetes. We also did not ...

Incretin-Based Therapies in Patients with Type 2 Diabetes

Several newer antidiabetes agents, in particular, incretin-based therapies, target the underlying defects of T2DM, provide glycemic control with beneficial ...

Incretin-based Therapy in Chronic Kidney Disease

Type 2 diabetes mellitus (T2DM) with concomitant CKD is an emerging clinical and public health prob- lem reaching epidemic proportions in the United States.

Louisiana Drug Utilization Review (LADUR) Education

The incretin system represents a novel treatment pathway for patients with type 2 diabetes. ... mended in patients with severe gastrointestinal ...

Tirzepatide versus Semaglutide Once Weekly in Patients with Type ...

Once-weekly injectable semaglutide, a selective GLP-1 receptor agonist, is approved for the treatment of type 2 diabetes at doses up to 1 mg. In trials ...

Initial management of hyperglycemia in adults with type 2 diabetes ...

Pharmacologic therapy — Pharmacotherapy targeted solely for weight management is effective in patients with type 2 diabetes. Although metformin ...

Variation in responses to incretin therapy: Modifiable and non ...

Type 2 diabetes (T2D) and obesity have reached epidemic proportions. Incretin therapy is the second line of treatment for T2D, improving both ...

Role of incretin hormones in the regulation of insulin secretion in ...

In patients with type 2 diabetes, however, the incretin effect is lost or greatly impaired. It is hypothesized that this loss explains an important part of the ...

Incretin and Pancreatic β-Cell Function in Patients with Type 2 ...

The improvement of β-cell incretin sensitivity by these different classes of anti-diabetic medications suggests a shared mechanism: the ...

GLP-1 Agonists: What They Are, How They Work & Side Effects

GLP-1 agonists are a class of medications that mainly help manage blood sugar (glucose) levels in people with Type 2 diabetes.

Incretin-Based Drugs and the Risk of Acute Pancreatitis

Findings In this international population-based study of 1.5 million patients with type 2 diabetes, compared with other antidiabetic drugs, the ...

Pharmacokinetics and Clinical Use of Incretin-Based Therapies in ...

Pharmacokinetics and Clinical Use of Incretin-Based Therapies in Patients with Chronic Kidney Disease and Type 2 Diabetes.

Introducing Incretin-Based Therapies: GLP-1 Receptor Agonists and ...

Another difference between the 2 incretin agents is that while DPP-4 inhibitors do not cause any change in weight [weight neutral], patients may experience a ...